Avivagen Inc. (VIV.V)
- Newsfile
Avivagen Makes Voluntary Assignment into Bankruptcy Under the BIA
Ottawa, Ontario--(Newsfile Corp. - April 24, 2024) - Avivagen Inc. (TSXV: VIV) ("Avivagen" or the "Company"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhance feed intake and support immune function, thereby supporting general health and performance, announced today that is has made a voluntary assignment in bankruptcy for the benefit of its creditors pursuant to section 49 of the Bankruptcy
- Business Wire
Avivagen Announces New 500Kg Order for OxC-beta™
OTTAWA, Ontario, October 17, 2023--Avivagen Inc. (TSXV.VIV) ("Avivagen" or the "Company"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, is pleased to announce a 500kg order for OxC-beta™. The purchase follows a 500kg order in July from the same customer, based in Taiwan, for use within the sow ma
- Business Wire
Avivagen Inc. Announces Results for the Third Quarter Ending July 31, 2023
OTTAWA, Ontario, September 29, 2023--Avivagen Inc. (TSXV:VIV) ("Avivagen"), a life sciences corporation focused on developing and commercializing products for livestock, companion animal and human applications that safely enhances feed intake and supports immune function, thereby supporting general health and performance, has announced its unaudited financial results for the third quarter of 2023.
